HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 138 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2015. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,895,484 | +9.5% | 75,798 | +2.9% | 0.01% | 0.0% |
| Q2 2023 | $2,645,167 | -11.0% | 73,659 | -5.3% | 0.01% | -14.3% |
| Q1 2023 | $2,970,761 | -20.4% | 77,789 | +18.6% | 0.01% | -30.0% |
| Q4 2022 | $3,732,982 | +44.1% | 65,606 | +0.1% | 0.01% | +42.9% |
| Q3 2022 | $2,591,000 | +19.5% | 65,529 | +33.0% | 0.01% | +16.7% |
| Q2 2022 | $2,169,000 | +539.8% | 49,283 | +492.2% | 0.01% | +500.0% |
| Q3 2021 | $339,000 | +3.0% | 8,322 | +14.9% | 0.00% | 0.0% |
| Q2 2021 | $329,000 | +7.2% | 7,241 | -1.7% | 0.00% | 0.0% |
| Q1 2021 | $307,000 | -20.1% | 7,364 | -18.0% | 0.00% | 0.0% |
| Q4 2020 | $384,000 | +71.4% | 8,979 | +5.5% | 0.00% | 0.0% |
| Q3 2020 | $224,000 | -87.3% | 8,512 | -91.6% | 0.00% | -98.3% |
| Q4 2015 | $1,759,000 | +85.4% | 101,492 | +43.7% | 0.06% | +48.7% |
| Q3 2015 | $949,000 | +16.0% | 70,624 | +95.0% | 0.04% | +50.0% |
| Q2 2015 | $818,000 | -17.0% | 36,224 | -47.5% | 0.03% | -21.2% |
| Q1 2015 | $985,000 | – | 68,976 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |